Integra

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Integra LifeSciences Holdings Corporation (IART) Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Friday, October 27, 2023
FDA, Telephone, Court, PMA, NEXT, LLP, Levi, COST, CLASS, Cryptocurrency, Dietary supplement, Integra

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Integra investors who were adversely affected by alleged securities fraud between March 11, 2019 and May 22, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    IART investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

IART INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Integra LifeSciences Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, October 31, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Food, Person, Court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Integra, Complaint

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/iart .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

IART INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Integra LifeSciences Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Monday, October 30, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Food, Person, Court, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Integra, Complaint

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) and certain of its officers.

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART) and certain of its officers.
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/iart .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

Retrieved on: 
Thursday, October 26, 2023
Suite, FDA, Lipopolysaccharide, News, Court, PMA, Integra, GPM, Defendant, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Integra Investors of a Lead Plaintiff Deadline of November 13, 2023

Retrieved on: 
Thursday, October 26, 2023
Vincent Wong, Attention, Law, Cryptocurrency, Integra

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders:

Key Points: 
  • NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention Integra LifeSciences Holdings Corporation ("Integra") (NASDAQ: IART) shareholders:
    The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between March 11, 2019 and May 22, 2023.
  • If you suffered a loss on your investment in Integra, contact us about potential recovery by using the link below.
  • There is no cost or obligation to you.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Integra LifeSciences Holdings Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - IART

Retrieved on: 
Thursday, October 26, 2023
Titan, FDA, Food, Court, I-Space (Chinese company), Advertising, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMA, Integra, Plaintiff, Class, Insurance, Tobacco

WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Integra class action, go to https://rosenlegal.com/submit-form/?case_id=19078 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Integra LifeSciences Holdings Corporation - IART

Retrieved on: 
Thursday, October 26, 2023
Integra, Tobacco, Security (finance)

CEDARHURST, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company’s shares between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • CEDARHURST, N.Y., Oct. 25, 2023 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company’s shares between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).
  • Shareholders have until November 13, 2023 to file lead plaintiff applications in the securities class action lawsuit.
  • Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.
  • The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

Reminder for IART Shareholders: Contact Robbins LLP for Information About the Integra Lifesciences Holding Corporation Class Action

Retrieved on: 
Wednesday, October 25, 2023
Integra, FDA, Person, Complaint, Boston, News, LLP, PMA, Lipopolysaccharide, SAN, Dietary supplement, Pharmaceutical industry

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • However, Integra had failed to take sufficient measures to remediate the violations identified by the FDA.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Integra Lifesciences Holdings Corporation.
  • Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by November 13, 2023.

INTEGRA LIFESCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Integra LifeSciences Holdings Corporation - IART

Retrieved on: 
Wednesday, October 25, 2023
Integra, FREE, Lawyer, District court, Financial adviser, Security (finance)

NEW ORLEANS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company’s shares between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).

Key Points: 
  • NEW ORLEANS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 13, 2023 to file lead plaintiff applications in a securities class action lawsuit against Integra LifeSciences Holdings Corporation (NasdaqGS: IART), if they purchased the Company’s shares between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).
  • This action is pending in the United States District Court for the District of New Jersey.
  • Integra investors should visit us at https://claimsfiler.com/cases/nasdaq-iart/ or call toll-free (844) 367-9658.
  • Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

Integra LifeSciences Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, October 25, 2023
Food, CSF, Amniotic fluid, ICP, Clarity, SIA, GAAP, Acquisition, Regulation of tobacco by the U.S. Food and Drug Administration, Maintenance (technical), Electrosurgery, TWC, Integra, Growth, Advanced Energy, EPS, CUSA, ...Continued, Total, Codman, Integra LifeSciences, Security (finance), Medical device, Pharmaceutical industry, Music, Video game, Bank, Instrument

PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.

Key Points: 
  • PRINCETON, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2023.
  • The Company reported GAAP gross margin of 57.1%, compared to 61.5% in the third quarter of 2022.
  • Adjusted EBITDA for the third quarter of 2023 was $88.1 million, or 23.0% of revenue, compared to $105.3 million, or 27.3% of revenue, in the prior year.
  • ET on Wednesday, October 25, 2023, to discuss third quarter 2023 financial results and forward-looking financial guidance.